| Cash Flow | 2025-06-30 |
|---|---|
| Share-based compensation | 60,395 |
| Non-cash financing costs | 3,044 |
| Amortization of operating lease right-of-use asset | 58,777 |
| Net loss | -10,427,632 |
| Prepaid expenses and other current assets | -805,527 |
| Operating lease liability | -62,027 |
| Other assets | -7,766 |
| Accrued expenses and other current liabilities | 66,118 |
| Deferred income | 0 |
| Accounts payable | 1,540,535 |
| Depreciation | 7,669 |
| Incentive tax receivable | -164,685 |
| Financing costs related to chef purchase agreement | 520,200 |
| Acquired in-process research and development | 114,399 |
| Net cash used in operating activities | -7,140,544 |
| Purchases of in-process research and development | 12,000 |
| Net cash used in investing activities | -12,000 |
| Proceeds from issuance of common stock, net of issuance costs | 7,803,453 |
| Payment of financing costs related to chef purchase agreement | 465,200 |
| Proceeds from exercise and modification of warrants, net of issuance costs | -13,868 |
| Payment of deferred offering costs | 0 |
| Net cash provided by financing activities | 7,324,385 |
| Net increase in cash | 171,841 |
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Sonnet BioTherapeutics Holdings, Inc. (SONN)